[Home ] [Archive]    
:: Home :: About Journal :: Registration :: Article Submission :: Contact us :: Site Map ::
:: Volume 7, Issue 4 (Summer 2015) ::
IJBC 2015, 7(4): 171-174 Back to browse issues page
A prospective Crossover Triple-blind Controlled Trial on the Safety and Efficacy of Iranian Recombinant FVIII (Safacto) versus Plasma Derived FVIII A pilot study
P Eshghi , H Abolghasemi , F Malek * , M Naderi , Y Panahi , B Habibpanah , E Fatohlahzadeh , F Gorji
Abstract:   (2890 Views)

Background: Considering the increasing number of patients with hemophilia and infrastructure requirements for a comprehensive approach, development of a recombinant factor has become a milestone. The objective of this study was to assess the safety, efficacy and non inferiority of Safacto (Recombinant factor VIII) compared with plasma-derived factor in the treatment of hemophilia A. Methods: 10 patients with severe hemophilia A were enrolled in this study. Each patient was treated by a 40-50 IU/kg infusion of either plasma derived or recombinant factor VIII after initiation of each of 4 consecutive hemarthrosis episodes in a triple-blind prospective crossover permuted block randomizing method. Clinical efficacy scale score and in vivo recovery of factor VIII was assessed in each of the treated bleeding episodes. Any adverse event was also recorded. Results: The mean±SD level of factor VIII in the plasma versus recombinant groups was 111.5±39 and 115±39, respectively without any significant difference. Response scaling method which assessed pain and range of motion revealed equalized scores along with in vivo recovery, hence treatment success rate was comparable in both groups. One non-recurring, mild skin rash reaction occurred simultaneous with the administration of plasma derived factor. Conclusion: Safacto (r-FVIII) is safe and effective and non-inferior to plasma derived factor VIII in the treatment of hemophilia A related bleeding events.

Keywords: Hemophilia A, Plasma derived factor VIII, Recombinant factor, Safacto
Full-Text [PDF 462 kb]   (1294 Downloads)    
: Research | Subject: Pediatric Hematology & Oncology
Accepted: 2015/10/20 | Published: 2015/09/9
* Corresponding Author Address: Pediatric Congenital Hematologic Disorders Research Center, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Add your comments about this article
Your username or Email:

Write the security code in the box >


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Eshghi P, Abolghasemi H, Malek F, Naderi M, Panahi Y, Habibpanah B, et al . A prospective Crossover Triple-blind Controlled Trial on the Safety and Efficacy of Iranian Recombinant FVIII (Safacto) versus Plasma Derived FVIII A pilot study. IJBC. 2015; 7 (4) :171-174
URL: http://ijbc.ir/article-1-624-en.html


Volume 7, Issue 4 (Summer 2015) Back to browse issues page
مجله ی خون و سرطان ایران Iranian Journal of Blood and Cancer
Persian site map - English site map - Created in 0.05 seconds with 31 queries by YEKTAWEB 3647